Japanese pharma selling drugs for prostate cancer (Xtandi), urology, transplant and ophthalmology.
Japanese pharma selling drugs for prostate cancer (Xtandi), urology, transplant and ophthalmology.
Sells branded prescription drugs through its own sales teams in Japan, Europe and elsewhere, while in the US it shares Xtandi and Padcev profit with Pfizer. Xtandi has long carried the company and faces patent expiry later this decade, so newer launches such as Veozah (menopausal hot flashes) and Izervay (an eye disease) matter.
Moat: narrow (IP / patents, distribution). Global partnership drugs (Xtandi with Pfizer, Padcev with Seagen) but facing upcoming patent cliffs.
Headquarters: Tokyo, Japan · Founded: 2005 · Employees: 14,099
Size Astellas Pharma (4503.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $31.4B, the 50th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,725 on 18 Nov 2026.
Performance Over six months the shares gained 17.2%, against +8.2% for the median peer and -1.4% for the Japan market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 18.6% over the last twelve months (peer median +16.4%); the operating margin is 23.4% (peer median 17.8%).
Valuation It trades at 12.9× forward earnings against a peer median of 22.9× (3rd cheapest of 19).
Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -20 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 12.4 points above its cost of capital (5.4% WACC).
Next results Next results expected around 8 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥2.38T | ¥2.14T | ¥1.91T | ¥1.60T | ¥1.52T |
| Revenue growth | — | +12% | +19% | +6% | — |
| Gross profit | ¥1.78T | ¥1.59T | ¥1.43T | ¥1.21T | ¥1.19T |
| EBITDA | ¥755B | ¥614B | ¥455B | ¥336B | ¥391B |
| Net income | ¥386B | ¥292B | ¥50.7B | ¥17.0B | ¥98.7B |
| Free cash flow | ¥497B | ¥509B | ¥165B | ¥143B | ¥296B |
| Capital expenditure | ¥111B | ¥84.6B | ¥57.3B | ¥82.5B | ¥88.5B |
| Total debt | ¥425B | ¥672B | ¥937B | ¥1.01T | ¥200B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Astellas Pharma 4503.T | $31.4B | +17% | +19% | 23% | 12.9× | -9.0% |
| Takeda Pharmaceutical 4502.T | $69.8B | +30% | +6% | 18% | 51.0× | 3.7% |
| Daiichi Sankyo 4568.T | $31.4B | +8% | +17% | 13% | 18.4× | 7.6% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 9.9× | -4.3% |
| Bayer BAYN.DE | $60.3B | +48% | 0% | 13% | 12.3× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4503.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +12.4% | +3.9% | 3rd highest of 21 |
| 6-month return | +17.2% | +8.2% | 9th highest of 21 |
| Distance from 52-week high | -1.6% | -10.3% | highest of 21 |
| Revenue growth (TTM) | +18.6% | +16.4% | 10th highest of 21 |
| Operating margin | 23.4% | 17.8% | 6th highest of 21 |
| Forward P/E | 12.9× | 22.9× | 3rd cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -9.0% | 10.5% | least demanding of 19 |
| Growth delivered (Del g) | +11.4% | +9.9% | 9th highest of 19 |
| Hurdle (Req g minus delivered) | -20.3 pp | +2.9 pp | 3rd least demanding of 19 |
| ROIC minus cost of capital | +12.4 pp | +4.8 pp | 8th highest of 21 |
| EV / EBITDA | 6.9× | 22.4× | cheapest of 18 |
| Net debt / EBITDA | 0.2× | -0.5× | 9th most indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Astellas Pharma 4503.T | Japan | $31.4B | +17% | +19% | 23% | 12.9× | -9.0% | +11.4% |
| Daiichi Sankyo 4568.T | Japan | $31.4B | +8% | +17% | 13% | 18.4× | 7.6% | +17.1% |
| Divi's Laboratories DIVISLAB.NS | India | $31.3B | +60% | +22% | 34% | 73.5× | 47.1% | +8.9% |
| Zoetis ZTS | United States | $34.8B | +7% | +1% | 37% | 13.8× | -2.9% | +7.2% |
| Roivant Sciences ROIV | United States | $28.1B | +20% | +102% | -3,234% | n/a | n/a | n/a |
| Biogen BIIB | United States | $37.2B | +34% | +2% | 17% | 17.1× | 10.1% | -5.1% |
| Insmed INSM | United States | $26.3B | +3% | +240% | -42% | n/a | n/a | n/a |
| Hansoh Pharma 3692.HK | Hong Kong | $25.3B | -3% | +25% | 38% | 25.8× | 7.9% | +10.8% |
| Royalty Pharma RPRX | United States | $39.4B | +29% | +11% | 66% | 11.5× | 10.8% | +2.3% |
| Haleon HLN.L | United Kingdom | $39.6B | 0% | +1% | 23% | 16.4× | 5.2% | +2.2% |
| Otsuka Hldgs 4578.T | Japan | $39.9B | +9% | +11% | 18% | 16.8× | 1.6% | +11.7% |
| Incyte INCY | United States | $24.0B | +21% | +25% | 12% | 15.1× | 14.2% | +14.0% |
| Sandoz SDZ.SW | Switzerland | $41.7B | +26% | +1% | 15% | 24.5× | 7.5% | +0.4% |
| Viatris VTRS | United States | $23.3B | +23% | +5% | 11% | 7.5× | 11.2% | +3.7% |
| Sigma Healthcare SIG.AX | Australia | $22.4B | +2% | +209% | 9% | 38.4× | 28.9% | +26.1% |
| Jiangsu Hengrui Pharmaceuticals 1276.HK | Hong Kong | $44.9B | -24% | +11% | 27% | 28.1× | 9.1% | +2.0% |
| BeOne Medicines 688235.SS | China | $45.5B | +9% | +25% | 18% | 59.7× | 19.1% | +79.3% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | India | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% | +11.7% |
| Alnylam Pharmaceuticals ALNY | United States | $20.0B | -50% | +56% | 20% | 21.2× | 0.5% | +49.8% |
| Galderma GALD.SW | Switzerland | $51.9B | +18% | +16% | 19% | 45.7× | 18.0% | +6.4% |
| Innovent Biologics 1801.HK | Hong Kong | $18.9B | +4% | +43% | 17% | 52.3× | 11.6% | +26.8% |